Molecules, Vol. 29, Pages 2095: The Role of Nanomedicine in Benign Gynecologic Disorders

Molecules, Vol. 29, Pages 2095: The Role of Nanomedicine in Benign Gynecologic Disorders Molecules doi: 10.3390/molecules29092095 Authors: Bethlehem A. Lulseged Malini S. Ramaiyer Rachel Michel Eslam E. Saad Bulent Ozpolat Mostafa A. Borahay Nanomedicine has revolutionized drug delivery in the last two decades. Nanoparticles appear to be a promising drug delivery platform in the treatment of various gynecological disorders including uterine leiomyoma, endometriosis, polycystic ovarian syndrome (PCOS), and menopause. Nanoparticles are tiny (mean size < 1000 nm), biodegradable, biocompatible, non-toxic, safe, and relatively inexpensive materials commonly used in imaging and the drug delivery of various therapeutics, such as chemotherapeutics, small molecule inhibitors, immune mediators, protein peptides and non-coding RNA. We performed a literature review of published studies to examine the role of nanoparticles in treating uterine leiomyoma, endometriosis, PCOS, and menopause. In uterine leiomyoma, nanoparticles containing 2-methoxyestradiole and simvastatin, promising uterine fibroid treatments, have been effective in significantly inhibiting tumor growth compared to controls in in vivo mouse models with patient-derived leiomyoma xenografts. Nanoparticles have also shown efficacy in delivering magnetic hyperthermia to ablate endometriotic tissue. Moreover, nanoparticles can be used to deliver hormones and have shown efficacy as a mechanism for tra...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research